These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34147205)

  • 41. Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy.
    Chettri A; Subba A; Singh GP; Bag PP
    J Pharm Pharmacol; 2024 Jan; 76(1):1-12. PubMed ID: 37934904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies.
    Schenck L; Erdemir D; Saunders Gorka L; Merritt JM; Marziano I; Ho R; Lee M; Bullard J; Boukerche M; Ferguson S; Florence AJ; Khan SA; Sun CC
    Mol Pharm; 2020 Jul; 17(7):2232-2244. PubMed ID: 32392068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Solid-state analysis of the active pharmaceutical ingredient in drug products.
    Newman AW; Byrn SR
    Drug Discov Today; 2003 Oct; 8(19):898-905. PubMed ID: 14554018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model.
    Carino SR; Sperry DC; Hawley M
    J Pharm Sci; 2010 Sep; 99(9):3923-30. PubMed ID: 20564336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.
    Ross SA; Lamprou DA; Douroumis D
    Chem Commun (Camb); 2016 Jul; 52(57):8772-86. PubMed ID: 27302311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanical Activation by Ball Milling as a Strategy to Prepare Highly Soluble Pharmaceutical Formulations in the Form of Co-Amorphous, Co-Crystals, or Polymorphs.
    Martínez LM; Cruz-Angeles J; Vázquez-Dávila M; Martínez E; Cabada P; Navarrete-Bernal C; Cortez F
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
    Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
    Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polymorphism of Indomethacin in Semicrystalline Dispersions: Formation, Transformation, and Segregation.
    Van Duong T; Lüdeker D; Van Bockstal PJ; De Beer T; Van Humbeeck J; Van den Mooter G
    Mol Pharm; 2018 Mar; 15(3):1037-1051. PubMed ID: 29307188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
    Elder DP; Holm R; Diego HL
    Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges.
    Cerreia Vioglio P; Chierotti MR; Gobetto R
    Adv Drug Deliv Rev; 2017 Aug; 117():86-110. PubMed ID: 28687273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The importance of characterizing the crystal form of the drug substance during drug development.
    Clas SD
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):550-60. PubMed ID: 12951818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of mid-IR spectroscopy for the characterization of pharmaceutical systems.
    Van Eerdenbrugh B; Taylor LS
    Int J Pharm; 2011 Sep; 417(1-2):3-16. PubMed ID: 21167267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphism in Simvastatin: Twinning, Disorder, and Enantiotropic Phase Transitions.
    Simões RG; Bernardes CES; Joseph A; M Piedade MF; Kraus W; Emmerling F; Diogo HP; Minas da Piedade ME
    Mol Pharm; 2018 Nov; 15(11):5349-5360. PubMed ID: 30230340
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous, one-step synthesis of pharmaceutical cocrystals via hot melt extrusion from neat to matrix-assisted processing - State of the art.
    Gajda M; Nartowski KP; Pluta J; Karolewicz B
    Int J Pharm; 2019 Mar; 558():426-440. PubMed ID: 30664997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients.
    Talaczynska A; Dzitko J; Cielecka-Piontek J
    Curr Pharm Des; 2016; 22(32):4975-4980. PubMed ID: 27494530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.